Oct 21, 2016 at 14:47 | Source: CNBC-TV18
Canadian drug regulator Health Canada may soon allow Dr Reddy's Labs to reinstate exports from its Srikakulam facility, according to people privy to the development, reports CNBC-TV18's Ekta Batra. The move may also mean a go-ahead from US FDA as well for exports from the Andhra Pradesh facility.
Oct 18, 2016 at 13:40 | Source: CNBC-TV18
The Maharashtra FDA is checking branded and un-branded lipsticks to check for traces of mercury, which is not permissible in cosmetics. Big companies like Lakme, Revlon and LOreal are under the scanner.
Oct 17, 2016 at 10:48 | Source: PTI
"The company's Gagillapur facility located in Hyderabad, Telangana... has successfully completed US FDA inspection without any observations," Granules India said in a BSE filing.
Oct 17, 2016 at 08:40 | Source: Moneycontrol.com
Granules India Ltd has informed BSE that Companys Gagillapur facility located at Hyderabad, Telangana, India has successfully completed US FDA inspection without any observations. This facility manufactures Finished Dosages (FDs) and Pharmaceutical Formulation Intermediates (PFIs).
Oct 16, 2016 at 12:36 | Source: PTI
Domestic pharmaceutical companies are likely to report subdued sales, EBITDA and PAT figures in the second quarter of this fiscal, even as the formulations business may see a strong recovery, Reliance Securities said in its report.
Oct 15, 2016 at 13:00 | Source: CNBC-TV18
In an exclusive interview with CNBC-TV18, Pankaj Patel said that the pricing pressure in US is cyclical in nature and competition is going to exist in the generic medicine market in US.
Oct 13, 2016 at 16:38 | Source: CNBC-TV18
Granules India gets US FDA approval for orange-coloured 200 mg version of ibuprofen. Speaking to CNBC-TV18, C Krishna Prasad said that the market for orange-coloured tablet is around USD 49 million.
Oct 13, 2016 at 12:24 | Source: PTI
"US FDA has approved Abbreviated New Drug Application (ANDA) for Ibuprofen tablets USP, 200 mg (OTC) filed by Granules India Ltd," the company said in a BSE filing.
Oct 05, 2016 at 11:46 | Source: PTI
"The company's formulation facility located at Panelav has received the Establishment Inspection Report (EIR) from US Food and Drug Administration (FDA) for the inspection carried out by them in March 2016," Alembic Pharmaceuticals said in a BSE filing.
Oct 05, 2016 at 07:55 | Source: Reuters
Medical device experts said they believe it was the first time a manufacturer had issued such a warning to patients about a cyber vulnerability, a hot topic in the industry following revelations last month about possible bugs in pacemakers and defibrillators.